В свете обнаружения рака предстательной железы, апиксабан похоже обладает наилучшим профилем эффективность/безопасность по сравнению с варфарином и иными DOAC:
Compared with warfarin, rates of bleeding (hazard ratio [95% confidence interval]) were similar in rivaroxaban (1.09 [0.79, 1.39]) and dabigatran (0.96 [0.72, 1.27]) users, whereas apixaban users experienced lower rates (0.37 [0.17, 0.79]). Rates of ischemic stroke did not differ among anticoagulant users. Compared with warfarin, rate of VTE (hazard ratio [95% confidence interval]) was lower among rivaroxaban (0.51 [0.41, 0.63]), dabigatran (0.28 [0.21, 0.38]), and apixaban (0.14 [0.07, 0.32]) users. In head-to-head comparisons among DOACs, dabigatran users had lower rates of VTE than rivaroxaban users; apixaban users had lower rates of VTE and severe bleeding than rivaroxaban users.
---
Blood Adv. 2018 Feb 13;2(3):200-209.
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
[Ссылки доступны только зарегистрированным пользователям ]
|